Global Health Limited (Medanta) filed its Business Responsibility and Sustainability Report (BRSR) for FY26 on August 21, 2026. The report covers environmental, social, and governance disclosures alongside the company's annual financial results.

The filing was made by Company Secretary Rahul Ranjan pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. An independent reasonable assurance report was provided by SGS India Private Limited for core indicators.

Financial and Operational Overview

Consolidated Total Income for FY26 increased 19.6% to ₹45,089 million. Profit After Tax rose 15.1% to ₹5,541 million. EBITDA before ESOP expenses stood at ₹10,560 million with a margin of 23.4%. Excluding the newly launched Noida hospital, EBITDA grew 18.6% to ₹11,343 million with a margin of 25.7%.

Inpatient volumes grew 16.0% to 2,02,112 while outpatient encounters rose 18.7% to 34,85,997. International patient revenues grew 33.2% to ₹2,780 million. The company closed with a net cash position of ₹5,906 million.

Environmental Disclosures

Total energy consumption was 3,23,641.86 GJ, with renewable sources contributing 36,479.15 GJ. Energy intensity per rupee of turnover decreased to 0.73 GJ/Lakh ₹ from 0.87 in FY25. Total water withdrawal reached 6,19,791.96 kilolitres, with total consumption at 5,98,777.55 kilolitres.

Scope 1 emissions totaled 5,006.55 MT CO2e and Scope 2 emissions were 41,059.44 MT CO2e. Combined emission intensity per rupee of turnover fell to 0.12 MTCO2e/Lakhs Rs from 0.14 in FY25. Total waste generated increased to 3,033.59 metric tonnes from 2,071.71 metric tonnes in FY25.

Social and Governance Metrics

The total workforce stood at 14,777 employees, with women comprising 50.8% of the permanent workforce. Gross wages paid to females accounted for 29% of total wages, down from 32% in FY25. The company reported zero fatalities and a Lost Time Injury Frequency Rate of nil.

Grievance redressal mechanisms recorded 16,178 customer complaints filed during FY26, with 533 pending resolution. There were no data privacy or cybersecurity complaints. The Board of Directors included two female members, representing 20% representation.

Expansion and AGM Details

Medanta added 623 beds across its network during FY26, bringing total installed capacity to 3,665 beds as of March 31, 2026. This included 382 beds at Noida, 131 at Patna, and 110 at Ranchi. The 22nd Annual General Meeting is scheduled for September 16, 2026, proposing a final dividend of ₹0.50 per equity share.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE474Q01031/5b3118fb-04d7-4275-8720-1773de615f0a.pdf

Global Health Limited will host a virtual analyst meeting on August 21, 2026, as part of its ongoing engagement with institutional investors. The company disclosed the schedule in a filing dated August 18, 2026, confirming that management will participate in a one-to-one session with First Ray Capital based in Singapore.

The interaction is structured as a standard investor dialogue rather than a broad conference call. Global Health Limited emphasised that no unpublished price-sensitive information (UPSI) is proposed to be shared during the discussion. This aligns with regulatory norms requiring equal information access for all market participants.

Meeting details

The specific parameters of the scheduled engagement are outlined below:

Rahul Ranjan, Company Secretary and Compliance Officer at Global Health Limited, signed the intimation. He noted that the schedule remains subject to change in the event of unforeseen circumstances involving the analysts, investors, or the company.

Regulatory context

The disclosure was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates timely disclosure of material events and ensures transparency in interactions between listed entities and financial intermediaries.

Global Health Limited listed this update under reference number GHL/2026-27/EXCH/41. The filing was directed to the listing departments of both BSE Limited and the National Stock Exchange of India Limited.